Vaxil Bio Ltd.

Vaxil Bio Ltd. is a biotechnology company specializing in immunotherapy with a focus on innovative drug discovery and development centered around signal peptides. Established in 2006, the company primarily targets solutions for infectious diseases and cancer. Notably, Vaxil Bio Ltd. has developed ImMucin, a vaccine derived from the MUC1 signal peptide, which has completed Phase 1/2 clinical trials for the treatment of multiple myeloma. Beyond oncology, the company is also advancing vaccine and treatment candidates for COVID-19 and tuberculosis, leveraging its proprietary platform technology. With its research and development activities primarily rooted in Israel and corporate headquarters in Toronto, Vaxil Bio Ltd. seeks to address unmet medical needs in both the immunotherapy and infectious disease sectors, contributing to advancements in targeted therapeutic interventions.